Systemic Akt1 Deletion after Tumor Onset in p53-/- Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration

Cell Reports

Volumn 12, Issue 4, 2015, Pages 610-621

  Yu, Wan Ni ^a   Nogueira, Veronique ^a   Sobhakumari, Arya ^a   Patra, Krushna C ^a,c   Bhaskar, Prashanth T ^a   Hay, Nissim ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AKT1 PROTEIN; CYCLIN D1; FAS LIGAND; PROTEIN KINASE B; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN 2; TAMOXIFEN; UNCLASSIFIED DRUG; AKT1 PROTEIN, MOUSE; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE ACTIVATION; LIFESPAN; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; THYMOCYTE; THYMUS LYMPHOMA; ANIMAL; APOPTOSIS; GENETICS; HUMAN; LONGEVITY; LYMPHOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HUMANS; LONGEVITY; LYMPHOMA; MICE; PROTO-ONCOGENE PROTEINS C-AKT; S-PHASE KINASE-ASSOCIATED PROTEINS; THYMOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84947028687     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.06.057     Document Type: Article

References (34)

1. Agarwal, A., Bumm, T.G., Corbin, A.S., O'Hare, T., Loriaux, M., VanDyke, J., Willis, S.G., Deininger, J., Nakayama, K.I., Druker, B.J., and Deininger, M.W. (2008). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 112, 1960-1970.
2. Bashir, T., Pagan, J.K., Busino, L., and Pagano, M. (2010). Phosphorylation of Ser72 is dispensable for Skp2 assembly into an active SCF ubiquitin ligase and its subcellular localization. Cell Cycle 9, 971-974. Bhaskar, P.T., and Hay, N. (2007). The two TORCs and Akt. Dev. Cell 12, 487-502.
3. Bhaskar, P.T., and Hay, N. (2007). The two TORCs and Akt. Dev. Cell 12, 487-502.
4. Chen, W.S., Xu, P.Z., Gottlob, K., Chen, M.L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203-2208.
5. Chen, M.L., Xu, P.Z., Peng, X.D., Chen, W.S., Guzman, G., Yang, X., Di Cristofano, A., Pandolfi, P.P., and Hay, N. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 20, 1569-1574.
6. Choi, Y.J., Saez, B., Anders, L., Hydbring, P., Stefano, J., Bacon, N.A., Cook, C., Kalaszczynska, I., Signoretti, S., Young, R.A., et al. (2014). D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev. Cell 30, 255-267.
7. Embree-Ku, M., and Boekelheide, K. (2002). FasL deficiency enhances the development of tumors in p53+/- mice. Toxicol. Pathol. 30, 705-713.
8. Gao, D., Inuzuka, H., Tseng, A., Chin, R.Y., Toker, A., and Wei, W. (2009). Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat. Cell Biol. 11, 397-408.
9. Giuriato, S., Ryeom, S., Fan, A.C., Bachireddy, P., Lynch, R.C., Rioth, M.J., van Riggelen, J., Kopelman, A.M., Passegué , E., Tang, F., et al. (2006). Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin- 1 to reverse the angiogenic switch. Proc. Natl. Acad. Sci. USA 103, 16266-16271.
10. Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P.K., Pan, B.S., and Kotani, H. (2010). MK- 2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956-1967.
11. Hollander, M.C., Maier, C.R., Hobbs, E.A., Ashmore, A.R., Linnoila, R.I., and Dennis, P.A. (2011). Akt1 deletion prevents lung tumorigenesis by mutant K-ras. Oncogene 30, 1812-1821.
12. Jiang, F., Caraway, N.P., Li, R., and Katz, R.L. (2005). RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 24, 3409-3418.
13. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M.P., Russell, R.G., et al. (2007). Akt1 governs breast cancer progression in vivo. Proc. Natl. Acad. Sci. USA 104, 7438-7443.
14. Kang-Decker, N., Tong, C., Boussouar, F., Baker, D.J., Xu, W., Leontovich, A.A., Taylor, W.R., Brindle, P.K., and van Deursen, J.M. (2004). Loss of CBP causes T cell lymphomagenesis in synergy with p27Kip1 insufficiency. Cancer Cell 5, 177-189.
15. Kennedy, S.G., Wagner, A.J., Conzen, S.D., Jordán, J., Bellacosa, A., Tsichlis, P.N., and Hay, N. (1997). The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11, 701-713.
16. Latres, E., Chiarle, R., Schulman, B.A., Pavletich, N.P., Pellicer, A., Inghirami, G., and Pagano, M. (2001). Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA 98, 2515-2520.
17. Lee, S.H., and McCormick, F. (2005). Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J. Mol. Med. 83, 296-307.
18. Lin, H.K., Wang, G., Chen, Z., Teruya-Feldstein, J., Liu, Y., Chan, C.H., Yang, W.L., Erdjument-Bromage, H., Nakayama, K.I., Nimer, S., et al. (2009). Phosphorylation- dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat. Cell Biol. 11, 420-432.
19. Malkin, D. (2011). Li-fraumeni syndrome. Genes Cancer 2, 475-484.
20. Maroulakou, I.G., Oemler, W., Naber, S.P., and Tsichlis, P.N. (2007). Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 67, 167-177
21. Martins, C.P., Brown-Swigart, L., and Evan, G.I. (2006). Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334.
22. Maurer, U., Charvet, C., Wagman, A.S., Dejardin, E., and Green, D.R. (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21, 749-760.
23. Nakayama, K., Nagahama, H., Minamishima, Y.A., Miyake, S., Ishida, N., Hatakeyama, S., Kitagawa, M., Iemura, S., Natsume, T., and Nakayama, K.I. (2004). Skp2-mediated degradation of p27 regulates progression into mitosis. Dev. Cell 6, 661-672.
24. Nogueira, V., Sundararajan, D., Kwan, J.M., Peng, X.D., Sarvepalli, N., Sonenberg, N., and Hay, N. (2012). Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. EMBO J. 31, 1134-1146.
25. Pagano, M. (2004). Control of DNA synthesis and mitosis by the Skp2-p27- Cdk1/2 axis. Mol. Cell 14, 414-416.
26. Skeen, J.E., Bhaskar, P.T., Chen, C.C., Chen, W.S., Peng, X.D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., and Hay, N. (2006). Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell 10, 269-280.
27. Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L.A., Jr., Kinzler, K.W., Vogelstein, B., and Papadopoulos, N. (2009). A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 106, 3964-3969.
28. Totary-Jain, H., Sanoudou, D., Dautriche, C.N., Schneller, H., Zambrana, L., and Marks, A.R. (2012). Rapamycin resistance is linked to defective regulation of Skp2. Cancer Res. 72, 1836-1843.
29. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., and Jacks, T. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665.
30. Walker, K.S., Deak, M., Paterson, A., Hudson, K., Cohen, P., and Alessi, D.R. (1998). Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha. Biochem. J. 331, 299-308.
31. Wang, H., Bauzon, F., Ji, P., Xu, X., Sun, D., Locker, J., Sellers, R.S., Nakayama, K., Nakayama, K.I., Cobrinik, D., and Zhu, L. (2010a). Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice. Nat. Genet. 42, 83-88.
32. Wang, Y., Suh, Y.A., Fuller, M.Y., Jackson, J.G., Xiong, S., Terzian, T., Quintás-Cardama, A., Bankson, J.A., El-Naggar, A.K., and Lozano, G. (2011). Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J. Clin. Invest. 121, 893-904.
33. Wendel, H.G., Silva, R.L., Malina, A., Mills, J.R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., and Lowe, S.W. (2007). Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232-3237.
34. Xu, P.Z., Chen, M.L., Jeon, S.M., Peng, X.D., and Hay, N. (2012). The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene 31, 518-526.